EP263/#849 Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: characterization of long-term/short-term treatment duration in light

Ying Liu,Lucy Gilbert,Destin Black,Adam Einaggar,Colleen Mccormick,Karen Cadoo,Rosie Taylor,Cara Mathews,Alon Altman,Diane Provencher,Jiefen Munley,Carol Aghajanian,Fiona Simpkins,Nashwa Kabil,Alan Barnicle

doi:10.1136/ijgc-2022-igcs.354

EP263/#849 Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: characterization of long-term/short-term treatment duration in light

Ying Liu, Lucy Gilbert + Show 13 more

Open Access

https://doi.org/10.1136/ijgc-2022-igcs.354

Copy DOI

Journal: International Journal of Gynecologic Cancer

Publication Date: Dec 1, 2022

Affiliation: Memorial Sloan Kettering Cancer Center, McGill University Health Centre, Willis-Knighton Cancer Center, West Cancer Center, AstraZeneca (United Kingdom), Women & Infants Hospital of Rhode Island, Brown University, CancerCare Manitoba, University of Manitoba, Centre Hospitalier de l’Université de Montréal, National Patient Safety Foundation, AstraZeneca (United States), University of Pennsylvania

#Homologous Recombination Deficiency Status #Platinum-sensitive Relapsed Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesThe LIGHT study (NCT02983799) demonstrated the activity of olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status (Mathews...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: International Journal of Gynecologic Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.